Mitapivat has 8 known drug interactions based on U.S. FDA drug labeling data. Of these, 5 are contraindicated combinations that should be avoided entirely. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Androgen-Deprivation Therapeutic Drugs, Anti-Platelet Agents, Cyp3a Inducers. Patients taking Mitapivat should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 8
- Contraindicated
- 5
- Major
- 1
- Moderate
- 2
Contraindicated (5)
- Mitapivat + Androgen-Deprivation Therapeutic Drugs— PYRUKYND may affect CYP2B6 substrates with narrow therapeutic index. Avoid concomitant use.
- Mitapivat + Anti-Platelet Agents— PYRUKYND may affect P-gp substrates with narrow therapeutic index. Avoid concomitant use.
- Mitapivat + Cyp3a Inducers— Co-administration decreases mitapivat plasma concentrations, reducing efficacy of PYRUKYND. Avoid concomitant use.
- Mitapivat + Mao Inhibitors— Co-administration increases mitapivat plasma concentrations, increasing risk of adverse reactions. Avoid concomitant use…
- Mitapivat + Sensitive Cyp3a Substrates With Narrow Therapeutic Index— PYRUKYND induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomita…
Major (1)
- Mitapivat + Ethinyl Estradiol— PYRUKYND induces CYP3A, decreasing systemic concentrations of this hormonal contraceptive. Monitor for loss of contracep…
Moderate (2)
- Mitapivat + P-Gp Or Bcrp Substrates— Monitor patients for adverse reactions of substrates with narrow therapeutic index.
- Mitapivat + Sensitive Cyp3a Substrates— Mitapivat induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomit…